JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B
in vitro (IC
50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively).
1 It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β.
1 JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC
50 values range from 112 to 514 nM), with lower potency against normal cells (IC
50 values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice.
1 JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein.
2 
